PPT-“TAVR: Transcatheter Treatment of Aortic Stenosis Comes of Age

Muhammad Raza MD FACC FSCAI RPVI Interventional cardiologist Director Cardiac Cath Lab Crozer Chester Medical Center Upland PA Disclosure Consultant and Proctor Medtronic. Kunjan Bhatt MD. Austin Heart. Let’s . Start off with some questions!. Question 1. Components for the continuity equation for AVA include all the following except? . 1. MV annular diameter. 2. MV annular VTI. The PARTNER Trial Cohort B 2-Year Results. The information in this slide deck is intended for educational purposes only, and should be read and used in its entirety.. Background. 3. September 22, 2010 on . The PARTNER Trial Cohort B 2-Year Results. The information in this slide deck is intended for educational purposes only, and should be read and used in its entirety.. Background. 3. September 22, 2010 on . -. takayasu. disease. -giant cell . arteritis. -. spondyloarthropathies. -. behcet. syndrome. -RA. Aortic Valve Replacement Resource Manual. Molina Allen. Overview. Identified need for resource manual:. Transcatheter. Aortic Valve Replacement (TAVR). Transition of Care. A2 .  A3. TAVR is approved for “. . . Severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement, and in who existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis” (Edwards Life Sciences, 2015).. perspective aortic stenosis is associated with a high mortalityformed. There is an especially high risk of deaththe functional state of the left ventricle; in addition,condition stabilized. It is poss 1 Disclosure Statement of Financial InterestsWithin the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below.Financial RelationshipCompanyRe Dr Monet Philipose. Jr3 Medicine. A Heart Team Perspective. Interventional cardiology: . Megan Coylewright, MD MPH FSCAI. Dartmouth-Hitchcock Heart and Vascular Center. Cardiac surgery: . Melissa Levack, MD. Vanderbilt University Medical Center. Shinichi Fukuhara, MD . (. 1,4,5). , Stephane Leung, MD (2,4,5), Daizo Tanaka, MD (3,4), Devraj Sukul, MD (1,5), P. . . Michael Grossman, MD (1,5), Stanley J. Chetcuti, MD (1,5), Chang He, PhD (4,5), Melissa Clark, MSN (4,5), Himanshu J. Patel, MD (1,4,5). D. on’t . L. ook . R. ight . …. . Chris Pan, MD. MBA. MS.. Interventional Cardiology. University of California, Irvine. Disclosures. None. Content. Valvular. heart disease. Aortic disease. Mimicker of aortic stenosis. EHJ-CR-D-22-00342. July 2022. Introduction. EHJ-CR-D-22-00342. 2. Transcatheter aortic valve replacement (TAVR) is becoming increasingly prevalent worldwide. In 2019 the number of TAVR performed in the USA exceeded surgical aortic valve replacements (SAVR), 72,991 vs 57,626.. Gregory Condos, MD, LCDR, MC, USN; Katherine Rees; Rasleen Grewal; Hirsch Mehta, MD; Raghava Gollapudi, MD; Karl Limmer, MD; Arvin Narula, MD. Disclosures. The authors have no relevant financial disclosures.. By: Cole Smith PharmD Candidate 2021. University of Findlay. Preceptor: Katherine Crawford PharmD BCCP. POPular. TAVI Cohort B Trial Review. Background:. TAVI/TAVR- Transcatheter aortic valve implant/replacement. Utilized for patients who have aortic stenosis to help when their valve is not opening correctly. .